Share on StockTwits

Keryx Biopharmaceuticals (NASDAQ:KERX) has been given a consensus rating of “Buy” by the eleven ratings firms that are covering the stock, Analyst Ratings News reports. Eight investment analysts have rated the stock with a buy rating, The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $23.89.

A number of research firms have recently commented on KERX. Analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $32.00 to $30.00 in a research note on Friday. Analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Friday, May 23rd. They now have a $19.00 price target on the stock.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 2.16% during mid-day trading on Monday, hitting $16.07. The stock had a trading volume of 404,482 shares. Keryx Biopharmaceuticals has a 52-week low of $8.29 and a 52-week high of $17.46. The stock’s 50-day moving average is $15.09 and its 200-day moving average is $14.83. The company’s market cap is $1.470 billion.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.14) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.88 earnings per share for the current fiscal year.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.